Introduction
Multiple myeloma (MM) remains a fatal B-cell malignancy with a median survival of less than 5 years. 1, 2 The major hurdle for a cure is the survival of residual tumor cells, even after repeated courses of high-dose chemotherapy followed by the infusion of peripheral blood progenitor cells (PBPCs). 3 Relapse can be delayed, but not avoided, by maintenance treatment during remission. Steroids and IFN-a have been extensively used for this purpose after conventional chemotherapy, and to a lesser extent after high-dose chemotherapy. [4] [5] [6] A better understanding of tumor-host interactions and the development of nonmyeloablative allografting have paved the way to novel strategies for the management of remission. Illustrative examples are: (1) antiangiogenic therapy with thalidomide or thalidomide analogs, sometimes associated with steroids; 7, 8 (2) passive immunotherapy with humanized or chimeric antibodies; 9,10 (3) adoptive immunotherapy with conventional or nonmyeloablative allografting; and [11] [12] [13] (4) active specific immunotherapy with protein-or dendritic cell (DC)-based vaccine formulations. 14, 15 Conventional allografting has proved to be the most effective to eliminate residual tumor cells, 16, 17 but its toxicity has limited its applicability. Nonmyeloablative allografting has given promising results, but its long-term efficacy is uncertain.
We have explored the feasibility of autologous vaccination as a maintenance treatment after high-dose chemotherapy and PBPC infusion. The idiotype (Id)-specific protein was conjugated to keyhole limpet hemocyanin (KLH) and delivered subcutaneously (s.c.) in the presence of GM-CSF as immunoadjuvant. The short-term immunological and clinical outcome of our initial series of 10 patients have already been reported. 14 Here, we report our expanded experience and long-term follow-up of 15 patients.
Materials and methods

Patient characteristics, vaccine preparation and treatment schedule
A total of 15 patients (Table 1 ) entered this study from August 1995 to July 1998. Their Durie and Salmon stages were: 11 stage III and four stage II; one was substage B. Eight patients were IgG, six IgA and one Bence Jones myeloma. All patients were in first remission after high-dose chemotherapy followed by PBPC infusion. Remission was defined as a 50% or more reduction of serum myeloma protein, 90% or more decrease of Bence Jones proteinuria, and 50% or more reduction of bone marrow infiltration. Id/KLH conjugates were prepared as previously reported. 14, 18 Briefly, Id was purified from serum or urine by precipitation and chromatography, and conjugated to clinical grade KLH (Biosyn, Arzneimittel GmbH, Fellbach, Germany). Final aliquots of Id/KLH conjugates contained 0.5 mg of Id and KLH each per ml of physiologic saline. Id/KLH conjugates were tested for mycoplasma, fungi, bacteria, and endotoxin contamination, before vialing and storing at À201C.
Patients received s.c. injections of 0.5 mg of Id/KLH conjugates at time 0 and at 2, 6, 10, 14, 24, and 28 weeks. GM-CSF (Mielogen, Schering-Plough, Milano, Italy) at 150 mg/m 2 /day was administered s.c. close to the vaccination site for 5 days.
Immunological monitoring
Antibody responses to Id, KLH, and GM-CSF were evaluated by comparing prevaccination serum samples with those collected 1 month, 1 year, and 2 years after the last vaccination. IgM and IgG responses to KLH were evaluated as previously reported.
14 Anti-GM-CSF responses were evaluated as follows: prevaccine and postvaccine sera were diluted in PBS þ 5% FCS and dispensed in microplates coated with 10 mg/ml GM-CSF. After incubation for 1 h at room temperature (RT) and extensive washing, alkaline phosphatase (AP)-conjugated goat anti-human IgG (Cappel, Organon Teknica Corporation, West Chester, PA, USA) was added and incubated for 1 h at RT. The enzyme substrate solution was added after extensive washing and incubated for 10 min at 371C. Absorption was evaluated at an optical density of 405 nm with an ELISA microtiter plate reader (Titertek Multiskan Plus, Flow Laboratories, Milano, Italy).
Anti-Id IgM and IgG were determined with dedicated ELISA assays recently developed in our laboratory. Prevaccine and postvaccine sera, and reactivity to autologous Id (Id þ ) and isotype-related allogeneic Id (IdÀ) were head to head compared in each patient. To eliminate interference by circulating Id/antiId immune complexes, ELISA were adapted to isotype and lightchain Id expression (Battaglio et al., manuscript in preparation). Briefly, IgM and IgG antibodies were detected in IgA patients by a four-step ELISA as follows: microplates were coated with goat anti-human IgM or IgG, and prevaccine and postvaccine sera were added. Next, purified Id þ or IdÀ was added, and APconjugated goat anti-human IgA was added as the final step. IgM and IgG antibodies were detected in IgG patients by a four-step ELISA in which Id light-chain expression was exploited. This assay identifies Ig anti-Id, but does not distinguish between IgM and IgG. When this assay was performed in IgG-k patients, microplates were coated with rabbit anti-human Ig-l light chain. Next, prevaccine and postvaccine sera were added, and anti-Id IgM-l and IgG-l were captured. Purified Id þ or IdÀ (both IgGk) was added and AP-conjugated goat anti-human k light-chain was added as the final step. The same strategy was used to detect IgM and IgG antibodies in IgG-l patients, but specificity of anti-human Ig light-chain antibodies was reversed. All antibody and sera incubation steps were performed for 1 h at RT in PBS þ 2% BSA, while washes were performed with 0.05% Triton X-100 (Sigma, Milano, Italy). The enzyme substrate solution was added, and absorption was evaluated as described above.
Total serum IgE levels were assessed with a commercially available ELISA kit according to the manufacturer's instructions (Radim, Pomezia Terme, Italy). Briefly, prevaccine and postvaccine sera were dispensed into microplates coated with mouse monoclonal anti-IgE antibody. AP-conjugated polyclonal anti-IgE antibodies were added and incubated for 1 h at RT. The substrate-chromogen solution was added after extensive washing, and absorption was evaluated at an optical density of 405-450 nm.
Reactivity of IgE against Id þ and IdÀ was evaluated as follows. Microplates were coated with mouse monoclonal antiIgE antibody. Prevaccine and postvaccine sera were dispensed into microwells, and incubated for 1 h at RT. After extensive washing, purified Id þ or IdÀ was added in PBS þ 2% FCS and incubated for 1 h at RT. After washing, AP-conjugated goat antihuman IgA (IgA MM) or IgG (IgG MM) was added and incubated for 1 h at RT. The enzyme substrate solution was added after extensive washing and incubated for 10 min at 371C. Absorption was evaluated as already described. Lastly, IgE antibody to KLH was evaluated with a five-step ELISA. Microplates were coated with mouse anti-human IgE. Prevaccine and postvaccine sera were dispensed into microwells and purified KLH was added. After extensive washing, purified human IgG anti-KLH, isolated from hyperimmune sera of Id/KLH-treated MM patients, were added and AP-conjugated goat anti-human IgG dispensed as the final step.
The T-cell receptor (TCR)BV repertoire was performed by a two step RT-PCR reaction and CDR3 length distribution analysis, as previously reported. 19 We distinguished four CDR3 size distribution patterns: (1) normal, with a Gaussian distribution of BV-BC CDR3 fragments; (2) reactive, with one or more peaks above the normal Gaussian background; (3) deteriorated, in which the Gaussian distribution was replaced by two or more predominant peaks; and (4) single peak, with a prominent single peak. The TCRBV repertoire was evaluated in eight patients before vaccination, during vaccination, and 6 and 12 months after the last immunization.
Delayed type hypersensitivity (DTH) skin tests were performed in 13 patients at the end of the vaccination, by intradermal injection of Id þ alone. Skin biopsies were performed as previously reported.
14 The test was repeated 1 year after the last vaccination in two patients, and almost 2 years in one patient.
Clinical evaluation
Tumor burden was determined by assessing the serum level of the tumor-related heavy chain, the serum k/l light-chain ratio and Bence Jones proteinuria by nephelometry (Sanofi Diagnostics Pasteur, Paris, France). Plasma cell infiltration was determined by microscopic evaluation of bone marrow aspirates after May-Grü nwald-Giemsa staining. In two patients, bone marrow and peripheral blood were evaluated for the presence of residual myeloma cells by PCR, using oligonucleotide primers and probes derived from the tumor-specific Ig heavy-chain gene sequences, as previously reported. 20, 21 Progression-free survival (PFS) was measured from the date of remission achievement to the date of progression or last followup. Overall survival (OS) was measured from the date of diagnosis to the date of death or last follow-up. The date of PBPC transplantation was the reference time point used to calculate the PFS and OS in the case-matched analysis. Lastly, survival was also measured from the date of progression to the date of death or last follow-up.
Results
Immunologic responses
Anti-KLH IgM and IgG were found in nine out of 10 tested patients. IgG were detectable at high titers at the end of the vaccination and persisted for 2 years. High and long-lasting Idiotype vaccination in human myeloma M Coscia et al titers of IgG antibodies to GM-CSF were also detected in three out of 15 patients. A dedicated four-step ELISA detected anti-Id IgG in two IgA and one IgG patients. By contrast, anti-Id IgM were never detected in postvaccine sera, including samples that generated anti-Id IgG antibodies. The specificity of anti-Id antibodies was determined by comparing the reactivity of prevaccine and postvaccine sera with purified Id þ and IdÀ and crossreactivity was observed in all cases. Despite the absence of clinically relevant allergies induced by vaccination, the total counts of eosinophils increased in all 15 patients and postvaccine values were higher than prevaccine values (127761/ml vs 328779/ml), but the difference was not statistically significant. In 11 patients, the increase was associated with an increase of serum IgE levels. IgE specificity in these patients was investigated by determining the reactivity to KLH, and purified Id þ and IdÀ. Postvaccine sera from five patients contained anti-KLH IgE. Anti-Id IgE were also observed in five patients, but only one patient generated anti-KLH and anti-Id IgE. Id þ and IdÀ crossreactivity was observed in four patients, but side-by-side quantitation showed higher titers of reactivity towards Id þ . In one patient IgE reactivity was restricted to Id þ only. Soluble responses to the vaccine components are summarized in Table 2 .
The TCRBV repertoire was evaluated in eight patients by comparing the CDR3 distribution profiles before vaccination (prevax), during vaccination (weeks 16 and 32), and 6 and 12 months (weeks 56 and 78) after the last immunization ( Figure 1 ). On average, the time elapsed from the last chemotherapy and the first dose of vaccine was 10 months. A progressive recovery of TCR diversity was observed during vaccination and onwards, but not during the prevaccination period. At 6 months after the last immunization, the mean percentage of TCRBV subfamilies with polyclonal CDR3 size distribution was 52.9720.75% compared to 26.7717.8% before vaccination (P ¼ 0.05) (Figure 1 ). The recovery of TCR diversity was inversely related to the decrease of TCRBV subfamilies with reactive CDR3 size distribution (r ¼ À0.8240; P ¼ 0.01). Notably, a positive correlation was observed between the decrease of abnormal TCRBV subfamilies and the remission duration (r ¼ À0.7508; P ¼ 0.03).
DTH skin tests were performed in 13 patients 1 month after the last immunization, by intradermal injection of unconjugated Id þ alone. Local erythema and induration were observed in 11 patients (85%). The histologic assessments of skin biopsies taken at the site of Id þ challenge showed the presence of a perivascular lymphocyte infiltration immunohistochemically characterized by a CD3 þ cell population, with a slight prevalence of CD8 þ vs CD4 þ cells. A late DTH skin test was performed in two patients in remission for 1 year and one in remission for 2 years. In this single patient, immunohistochemical characterization of the positive DTH reaction showed a lymphocytic infiltrate mostly consisting of CD3 þ lymphocytes with similar proportions of CD8 þ and CD4 þ cells (see also Figure 2 ).
Clinical outcome
The median durations of follow-up are 110 months from diagnosis (range, 82-152 months) and 78 months from the start of vaccination (range, 62-90 months). The median OS from diagnosis is 82 months (range, 34-152 months), while the median PFS is 40 months (range, 17-139 months) when calculated from the date of remission (Figure 3) . Vaccination did not eliminate the residual tumor burden despite the generation of long-lasting and tumor-specific immune responses. An illustrative example is shown in Figure 2 . (Figure 4) . Matching was performed with respect to age, disease stage, and serum b2-microglobulin levels at diagnosis, and prior number of high-dose melphalan treatments. The time elapsed from the PBPC infusion to the start of maintenance treatment was similar in the vaccination and control group, with a median value of 9 and 6 months, respectively. The median PFS from the time of the transplant was 37 months in the vaccination group (range, 13-134 months) and 26 months in the control group (range, 4-83 months), while the median OS was 70 months (range, 25-134 months) in the former and 75 months (range, 5-109 months) in the latter. The median follow-up from the time of PBPC infusion was 86 months in the vaccination and 84 months in the control group. Any detrimental effect of vaccine on salvage chemotherapy was evaluated by calculating the survival from the date of progression to the date of death or last follow-up. The median survival was 31 months (range, 12-58 months) in the vaccine and 29 months (range, 1-75 months) in the control group. The difference was not statistically significant. Even if these data were obtained in a small series of patients, results are encouraging and worthy of further investigation.
Discussion
Id-based vaccine formulations modulate the immune system of MM patients, 14, 15, [22] [23] [24] [25] [26] [27] but the long-term clinical impact of this modulation has not been reported. Here, we report the longterm follow-up of 15 patients receiving Id vaccines as a maintenance therapy after high-dose chemotherapy and PBPC infusion. The median durations of follow-up are 110 months from diagnosis, 86 months after the PBPC transplantation, and 78 months after the start of vaccine therapy. This is the largest series of MM receiving active specific immunotherapy with the Generation of long-lasting Id-specific immune responses with cytostatic activity on the residual tumor burden. A representative patient with a very late positive DTH reaction to Id þ is shown in (a)-(d). The DTH reaction was positive 20 months after the last immunization. Unconjugated Id þ alone or an equivalent amount of polyclonal human Ig as a control were injected intradermally into the opposite forearms. Only the site of Id injection was characterized by local erythema and induration (a). The histologic assessment ( Â 40) of the skin biopsy taken at the site of Id þ challenge showed a perivascular lymphocyte infiltration (b). The immunoistochemical assessment of infiltrating lymphocytes showed similar proportions of CD8 þ (c) and CD4 þ cells (d). A PCR analysis of monoclonal plasma cells (e) and clonally related preswitch B cells (f) was also performed in the same patient to evaluate the effect of the ongoing Id-specific immune response on the residual tumor cells in the peripheral blood and bone marrow. Cg-and Cm-associated tumor-specific VDJ sequences were detected by nested PCR. Polyclonal B cells from hyperplastic lymph nodes were used as a control. The tumor-specific band was still present in the peripheral blood and bone marrow after vaccination.
Figure 3
Median PFS and OS of MM patients receiving Id vaccines. The median PFS (a) and OS (b) durations are 40 and 82 months, after a median follow-up of 110 months. PFS is calculated from the date of remission achievement and OS is calculated from the time of diagnosis.
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M Coscia et al longest follow-up reported in the setting of high-dose chemotherapy and autologous PBPC infusion. Most patients (90%) produced high titers of long-lasting anti-KLH IgM and IgG, indicating that their ability to generate primary immune response to highly immunogenic foreign proteins was preserved.
A novel finding was the detection of anti-Id IgG in 20% of patients. Previous reports have shown a higher frequency of humoral responses in MM receiving DC-based vaccines, [25] [26] [27] but no data are available on protein-based vaccines. Anti-Id IgG were detected by means of a dedicated four-step ELISA, not influenced by circulating Id/anti-Id immune complexes (Battaglio et al., manuscript in preparation). Low amounts of circulating Id, still present in the remission phase, could react with any anti-Id antibodies induced by the Id/KLH conjugates. This would explain the negative results previously observed when anti-Id antibodies were assessed by direct ELISA.
14 A possible caveat of the four-step indirect ELISA is the underestimation of the real frequency and titers of anti-Id antibodies because anti-IgG (for IgA MM)-or anti-light-chain antibodies (for IgG MM), rather than purified Id, are bound to plastic as a first layer to react with prevaccine and postvaccine sera. This approach enhances specificity, but lowers sensitivity. Head-tohead comparison showed that anti-Id IgG antibodies crossreacted with Id þ and IdÀ, indicating that immunization occurred against epitopes localized in the constant region rather than the variable regions of Id þ . This crossreactivity is in line with Trojan et al's 30 finding that human immunoglobulinderived peptides, which induce cytotoxic T-lymphocyte responses, are mostly derived from the framework rather than the hypervariable regions. Notably, anti-Id IgM were extensively investigated but never detected in any sample, including postvaccine sera from patients that generated anti-Id IgG. These data are consistent with the hypothesis that anti-Id, unlike anti-KLH antibody responses, are secondary immune responses. The immune system of MM patients has already been primed by Id, but memory T and B cells are kept under self-tolerance mechanisms. Mouse models are consistent with this scenario. 31, 32 Possible concerns of immunization against self-antigens, like Id and GM-CSF, are the induction of autoimmune responses or allergic reactions, and the development of neutralizing antibodies against endogenous cytokines or growth factors. Three out of 15 patients produced anti-GM-CSF IgG that, however, did not neutralize the biological activity of endogenous GM-CSF. These patients had peripheral counts of neutrophils, monocytes, and lymphocytes similar to patients who did not develop antibodies (data not shown). Moreover, anti-GM-CSF antibodies did not adversely affect the infection rate, leukopenia duration, and transfusion requirement when chemotherapy was given for relapse. Anti-GM-CSF antibodies have been reported in 72% of cancer patients receiving soluble GM-CSF as a vaccine adjuvant in an HER-2/neu peptide-based clinical trial. 28 These antibodies were not neutralizing and hematologic or infectious complications were not reported. Altogether, these data indicate that the probability of developing neutralizing antibodies is low when GM-CSF is given as a vaccine adjuvant in MM. Indeed, a high frequency of neutralizing antibodies has only been reported in nonimmunocompromised patients receiving high doses of GM-CSF. 29 Serum IgE levels increased in 11 of the 15 patients upon vaccination. In seven patients, IgE were 4100 UI/ml and between 20 and 100 UI/ml in four patients, but none had allergic disease. Interestingly, the same proportion of tested patients generated anti-KLH and anti-Id IgE, although the former is a strongly immunogenic foreign protein and the latter a self-antigen. There was no correlation between the production of anti-KLH and anti-Id IgE in individual patients, since only one generated both types. Four patients had crossreactive IgE, but, unlike anti-Id IgG antibodies, titers were uniformly higher with Id þ than IdÀ. Notably, one patient had IgE reacting with Id þ only. Since IgE class switching requires T-cell cooperation, the induction of Idspecific IgE further indicates that tolerance to tumor-derived self-antigens can be overcome in MM by appropriate antigen presentation.
The increase of IgE was associated with an increase of eosinophils in all patients, probably mediated by GM-CSF. An increase of eosinophils has already been reported in cancer patients receiving vaccine formulation with GM-CSF as immunoadjuvant. Metastatic patients receiving irradiated autologous melanoma cells, engineered to secret GM-CSF, had increased peripheral counts plus extensive eosinophilic infiltration at the vaccination site where local concentrations of GM-CSF were higher. 33 Despite the increase of eosinophils and IgE, allergic reactions did not occur during vaccination and onwards, with the exception of a 64-year-old woman who developed intolerance to dry raisins. In this patient, serum IgE levels were already high before vaccination (97 UI/ml), further increased during vaccination (204 UI/ml), and decreased to 108 UI/ml at the end of the It is a common belief that effective cancer immunotherapy requires a cooperative crosstalk between natural and adaptive immunity. Among effector mechanisms of adaptive immunity, Th1-driven immune responses are thought to play a major role in the elimination of tumor cells. The preferential Th-2 polarization observed in our study may be one explanation why immune responses were not robust enough to eliminate residual tumor cells. Monitoring of residual disease showed that tumor cells persisted over time even in patients who generated long-lasting and tumor-specific immune responses. Experimental and clinical data indicate that IL-12 can be profitably included in vaccine formulations to promote Th-1 polarization and the development of more robust cytolytic immune responses. 34, 35 This cytokine counterbalances the Th-2 polarizing activity of GM-CSF and restores the intrinsically defective Th-1 cytokine network of MM patients. 36 The TCR repertoire is determined by genetic and environmental factors, and is dynamically influenced by immune responses. Determination of the clonality and reciprocal usage of BV gene segments has shown that the TCR repertoire is severely disrupted in MM patients after high-dose chemotherapy and PBPC infusion. 19 On average, one-third consists of T cells expressing oligoclonal or abnormal TCRBV transcripts. 19 A progressive recovery of TCR diversity was observed following the start of vaccination, as shown by the increase of polyclonal and the decrease of abnormal TCRBV transcripts. A direct correlation was observed between the decrease of abnormal TCRBV subfamilies and the remission duration, indicating that the progressive recovery of TCR diversity has a positive impact on the disease control in vivo. This recovery of TCRBV diversity after PBPC transplantation is a multifactorial process, and Id vaccination can be a factor. In fact, abnormal TCRBV subfamilies tended to increase before vaccination (data not shown), and they started to decrease only after vaccination. These data indicate that the TCR repertoire of MM patients, highly skewed by the long-term exposure to tumor cells and the subsequent delivery of intensive chemotherapy, is still susceptible of modulation by Id vaccines.
Id vaccines modulated the immune system, but did not eliminate the residual tumor burden. An illustrative example was patient UPN 510, whose plasma cells and tumor-related preswitch B cells were still detectable by PCR 2 years after the last immunization even though they had been continuously exposed to Id-specific T cells generated by Id vaccines. Nevertheless, the median PFS and OS durations in vaccinated patients were 40 and 82 months, respectively, after a median follow-up of 110 months. To better determine the clinical impact of vaccination, we performed a retrospective casematched analysis with MM treated after high-dose chemotherapy and autologous PBSC transplantation with s.c. IFN-a 3 Â weekly and/or high doses of intermittent dexamethasone, repeated monthly. The date of transplant was the reference time point used for computation to compare PFS and OS duration between the two groups. The median PFS and OS durations were similar in the vaccine and the control group. These results, even if they have been observed in a small series of patients, are encouraging and deserve further investigations. We could not perform a retrospective case-matched analysis with patients who did not receive any maintenance therapy since, at our Institution, all patients in remission are on single-or multidrug regimens, including steroids, IFN-a, aminobisphosphonates and, more recently, thalidomide. The median survival from relapse was also similar in the vaccine and the control group, indicating that the immunomodulation induced by Id vaccination did not select more aggressive or less chemosensitive myeloma cell variants. Interestingly, two patients were treated after relapse with monthly courses of intermittent highdose dexamethasone and both achieved a stable disease status that lasted 10 and 12 months. Two patients treated with thalidomide alone or in association with steroids also achieved a stable status that lasted 14 and 22 months. Thus, a fraction of patients relapsing after Id vaccination remain amenable to alternative maintenance treatments that can further delay the delivery of salvage chemotherapy. In the remaining seven patients, the relapse was treated with chemotherapy followed by thalidomide treatment and all patients achieved a durable second remission.
Other groups have delivered Id-based vaccines as a maintenance treatment after high-dose chemotherapy. Id was delivered as a soluble protein in variable combination with haptens and/or adjuvants, 14 or delivered by DC to exploit their unique immunoadjuvant properties. 15, 24 DC were purified from the peripheral blood, 15 or generated from circulating monocytes 24 or purified CD34 þ cells. 27 Id-specific immune responses were observed, but had no significant impact on the residual tumor burden and the long-term clinical follow-up was not reported. Our study is the first to report the long-term followup of MM which mounted a cytostatic rather than cytolytic tumor-specific immune response upon the delivery of Id vaccination. Notably, the same vaccine formulation induced cytolytic immune responses in patients with low-grade lymphoma, even at the stage of minimal residual disease. 37 This difference may reflect the lower immunocompetence status of MM patients. Multiple dysfunctions have been reported by us and others in cell subsets that are key players in the generation of immune responses. 38, 39 A better understanding of tumor-host interactions and tailoring immunotherapy to the immunocompetence status of individual patients may further improve the efficacy of Id vaccines and win them a prominent position in the therapeutic armamentarium during remission.
